KR960702318A - 근육 질병 및 장애의 치료방법 - Google Patents

근육 질병 및 장애의 치료방법

Info

Publication number
KR960702318A
KR960702318A KR1019950704903A KR19950704903A KR960702318A KR 960702318 A KR960702318 A KR 960702318A KR 1019950704903 A KR1019950704903 A KR 1019950704903A KR 19950704903 A KR19950704903 A KR 19950704903A KR 960702318 A KR960702318 A KR 960702318A
Authority
KR
South Korea
Prior art keywords
disorders
treatment
muscle diseases
compounds
muscle
Prior art date
Application number
KR1019950704903A
Other languages
English (en)
Other versions
KR100284909B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR960702318A publication Critical patent/KR960702318A/ko
Application granted granted Critical
Publication of KR100284909B1 publication Critical patent/KR100284909B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019950704903A 1993-05-06 1994-05-06 근육 질병 및 장애 치료용 조성물 KR100284909B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5902293A 1993-05-06 1993-05-06
US8/059022 1993-05-06
US8/209204 1994-03-08
US08/209,204 US7115554B1 (en) 1993-05-06 1994-03-08 Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
PCT/US1994/005083 WO1994026298A1 (en) 1993-05-06 1994-05-06 Methods for treating muscle diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020000054080A Division KR100306244B1 (ko) 1993-05-06 2000-09-14 근육 질병 및 장애 치료용 조성물

Publications (2)

Publication Number Publication Date
KR960702318A true KR960702318A (ko) 1996-04-27
KR100284909B1 KR100284909B1 (ko) 2001-03-15

Family

ID=26738273

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019950704903A KR100284909B1 (ko) 1993-05-06 1994-05-06 근육 질병 및 장애 치료용 조성물
KR1020000054080A KR100306244B1 (ko) 1993-05-06 2000-09-14 근육 질병 및 장애 치료용 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020000054080A KR100306244B1 (ko) 1993-05-06 2000-09-14 근육 질병 및 장애 치료용 조성물

Country Status (10)

Country Link
US (5) US7115554B1 (ko)
EP (1) EP0703785B8 (ko)
JP (3) JP4035159B2 (ko)
KR (2) KR100284909B1 (ko)
AT (1) ATE299710T1 (ko)
AU (1) AU691810B2 (ko)
CA (1) CA2162262C (ko)
DE (1) DE69434431T2 (ko)
ES (1) ES2243928T3 (ko)
WO (1) WO1994026298A1 (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US7037888B1 (en) * 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
FR2731225B1 (fr) * 1995-03-03 2003-10-31 Pasteur Institut Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique
CN1651457B (zh) * 1994-10-20 2010-07-28 巴斯德研究所 Hiv-1 o组(或亚组)逆转录病毒抗原的核苷酸序列
DE69732711T2 (de) 1996-07-12 2006-03-16 Genentech, Inc., South San Francisco Gamma-heregulin
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
DK0970207T3 (da) 1997-02-10 2009-07-13 Genentech Inc Heregulin-varianter
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
EP1146893A1 (en) * 1998-12-11 2001-10-24 Tejvir S. Khurana Neurite derived growth factors for use in the treatment of muscular dystrophy
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6967102B1 (en) * 1999-03-11 2005-11-22 University Of Manitoba Nitric oxide manipulation of muscle satellite cell activation
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US7495147B2 (en) 2000-02-28 2009-02-24 Decode Genetics Ehf. Neuregulin-1 transgenic mouse and methods of use
CA2407656A1 (en) * 2000-04-27 2001-11-08 Kyowa Hakko Kogyo Co. Ltd. Myocardial cell proliferation-associated genes
EP1289553B1 (en) 2000-05-23 2011-07-13 CeNeS Pharmaceuticals, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2004030706A2 (en) * 2002-10-01 2004-04-15 Law Peter K Bioactive implants
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
RU2457854C2 (ru) * 2005-12-30 2012-08-10 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед Длительное высвобождение нейрегулина для улучшения сердечной функции
WO2008091867A2 (en) * 2007-01-22 2008-07-31 Children's Medical Center Corporation Periostin induces proliferation of cardiomyocytes and promotes cardiac regeneration
CN101743474B (zh) 2007-05-10 2015-06-03 阿索尔达治疗公司 检测心脏损伤的方法
US8354446B2 (en) 2007-12-21 2013-01-15 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (SARMs) and uses thereof
EP3632459A1 (en) 2008-07-17 2020-04-08 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
CN107041949A (zh) 2008-08-15 2017-08-15 阿索尔达治疗公司 在cns神经性损伤后非‑急性期间处理的组合物及方法
WO2010060265A1 (en) 2008-11-28 2010-06-03 Zensun (Shanghai) Science & Technology Limited Neuregulin peptides and their use
US20120121557A1 (en) * 2009-07-22 2012-05-17 Children's Medical Center Corporation Neuregulin induced proliferation of cardiomyocytes
JP2013529911A (ja) * 2010-05-28 2013-07-25 マインド−エヌアールジー ソシエテ アノニム ニューレグリンアイソフォーム、ニューレグリンポリペプチドおよびその使用法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
BR112015029293A2 (pt) 2013-05-22 2018-04-24 Zensun Shanghai Science & Tech Ltd método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero
KR102051433B1 (ko) * 2013-08-27 2020-01-08 (주)네오팜 근육 분화 촉진 및 근육 강화용 조성물 및 외용제
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
WO2021052277A1 (zh) 2019-09-16 2021-03-25 上海泽生科技开发股份有限公司 重组人神经调节蛋白衍生物及其用途
CN113289002A (zh) 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
EP4351722A1 (en) 2021-06-10 2024-04-17 Amgen Inc. Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5143842A (en) * 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech Inc Her2 extrazellulare domäne
US5464751A (en) 1990-04-06 1995-11-07 Trustees Of The University Of Pennsylvania Ligand for the neu gene product
WO1991018921A1 (en) 1990-05-25 1991-12-12 Georgetown University GROWTH FACTOR WHICH INHIBITS THE GROWTH OF CELLS OVEREXPRESSING THE HUMAN ONCOGENE erbB-2
CA2086264C (en) 1990-06-27 2002-12-24 Jeffrey L. Browning Surface complexed lymphotoxin
KR930703359A (ko) 1991-01-14 1993-11-29 조지 알. 라스니어 이알비비- 2(erbB-2) 수용체 단백질에 결합하고 세포 반응을 유도하는 리간드 성장인자
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5367060A (en) 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure

Also Published As

Publication number Publication date
KR100284909B1 (ko) 2001-03-15
US6444642B1 (en) 2002-09-03
EP0703785A1 (en) 1996-04-03
US7384756B1 (en) 2008-06-10
US8026213B2 (en) 2011-09-27
US7115554B1 (en) 2006-10-03
EP0703785A4 (en) 1998-12-30
DE69434431T2 (de) 2006-05-24
EP0703785B8 (en) 2005-09-14
ATE299710T1 (de) 2005-08-15
US20110144015A1 (en) 2011-06-16
US20090018073A1 (en) 2009-01-15
WO1994026298A1 (en) 1994-11-24
KR100306244B1 (ko) 2001-09-24
CA2162262A1 (en) 1994-11-24
AU691810B2 (en) 1998-05-28
JPH11507201A (ja) 1999-06-29
DE69434431D1 (de) 2005-08-25
EP0703785B1 (en) 2005-07-20
AU6827894A (en) 1994-12-12
US7718606B2 (en) 2010-05-18
JP2007332153A (ja) 2007-12-27
CA2162262C (en) 2011-07-12
JP4018028B2 (ja) 2007-12-05
JP2004043437A (ja) 2004-02-12
JP4035159B2 (ja) 2008-01-16
ES2243928T3 (es) 2005-12-01

Similar Documents

Publication Publication Date Title
KR960702318A (ko) 근육 질병 및 장애의 치료방법
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
NO20075065L (no) Anvendelse av isoflavonforbindelser til a behandle hjertesykdom
RU94013439A (ru) Гетероциклические соединения, способ их получения, фармацевтическая композиция и способ лечения
DE69232485T2 (de) VERWENDUNG VON RELAXIN zur Herstellung eines Arzneimittels für die Behandlung KARDIOVASKULÄREN Krankeiten.
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
FR2760369B1 (fr) Stimulateur cardiaque multisites pour le traitement des insuffisances cardiaques par stimulation
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE69626916D1 (de) Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
GR3032531T3 (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases
MX9602793A (es) Uso de sertralina para tratar pacientes despues de un infarto de miocardio.
DE69530600D1 (de) Verwendung von nk1-rezeptor antagonisten zur zubereitung von arzneimitteln mit kardioregulierender wirkung
BG102009A (en) Method for the treatment of manic and two-pole disease
RU93035807A (ru) Способ лечения юношеского эпифизиолиса

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
A107 Divisional application of patent
AMND Amendment
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20041227

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee